With 26,000 Participants, Phase-3 Trials Of 'Covaxin' Start: Bharat Biotech

Bharat Biotech Chairman Krishna Ella on November 16 said that the company's COVID-19 vaccine, Covaxin, has been undergoing phase-3 trails with over 26,000 participants. Krishna added that they were also working on a nasal vaccine, which could be available by 2021. The vaccine is being developed by the firm in association with the National Institute of Virology (NIV). Krishna also claimed that only Bharat Biotech had Biosafety Level-3 production facility.